Association of Bypass Surgery and Mortality in Moyamoya Disease
Authors:
- Hyunjun ParkHPHyunjun Park
- Minkyung HanMHMinkyung Han
- Dong‐Kyu JangDJDong‐Kyu Jang
- Dal‐Soo KimDKDal‐Soo Kim
- Pil‐Woo HuhPHPil‐Woo Huh
- Hae‐Kwan ParkHPHae‐Kwan Park
- Ik Seong ParkIPIk Seong Park
- Young‐Min HanYHYoung‐Min Han
- Jae Hoon SungJSJae Hoon Sung
- Kwan‐Sung LeeKLKwan‐Sung Lee
- Hyung‐Jin LeeHLHyung‐Jin Lee
- Young Woo KimYKYoung Woo Kim
Open Access
- 21 November 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (22) , e030834
Abstract
Background: Patients with moyamoya disease (MMD) have a high risk of stroke or death. We investigated whether extracranial to intracranial bypass surgery can reduce mortality by preventing strokes in patients with MMD. Methods and Results: This nationwide retrospective cohort study encompassed patients with MMD registered under the Rare Intractable Diseases program via the Relieved Co‐Payment Policy between 2006 and 2019, using the Korean National Health Insurance Service database. Following a 4‐year washout period, landmark analyses were employed to assess mortality and stroke occurrence between the bypass surgery group and the nonsurgical control group at specific time points postindex date (1 month and 3, 6, 12, and 36 months). The study included 18 480 patients with MMD (mean age, 40.7 years; male to female ratio, 1:1.86) with a median follow‐up of 5.6 years (interquartile range, 2.5–9.3; mean, 6.1 years [SD, 4.0 years]). During 111 775 person‐years of follow‐up, 265 patients in the bypass surgery group and 1144 patients in the nonsurgical control group died (incidence mortality rate of 618.1 events versus 1660.3 events, respectively, per 10 5 person‐years). The overall adjusted hazard ratio (HR) revealed significantly lower all‐cause mortality in the bypass surgery group from the 36‐month landmark time point, for any stroke mortality from 3‐ and 6‐month landmark time points, and for hemorrhagic stroke mortality from the 6‐month landmark time point. Furthermore, the overall adjusted HRs for hemorrhagic stroke occurrence were beneficially maintained from all 5 landmark time points in the bypass surgery group. Conclusions: Bypass surgery in patients with MMD was associated with a lower risk of all‐cause and hemorrhagic stroke mortality and hemorrhagic stroke occurrence compared with nonsurgical control.Keywords
This publication has 34 references indexed in Scilit:
- Clinical and Angiographic Features and Stroke Types in Adult Moyamoya DiseaseAmerican Journal of Neuroradiology, 2014
- Long term outcome after conservative and surgical treatment of haemorrhagic moyamoya diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya diseaseNeurology, 2012
- Guidelines for Diagnosis and Treatment of Moyamoya Disease (Spontaneous Occlusion of the Circle of Willis)Neurologia medico-chirurgica, 2012
- Extracranial-Intracranial Bypass Surgery for Stroke Prevention in Hemodynamic Cerebral IschemiaJAMA, 2011
- Landmark Analysis at the 25-Year Landmark PointCirculation: Cardiovascular Quality and Outcomes, 2011
- Immortal Time Bias in PharmacoepidemiologyAmerican Journal of Epidemiology, 2007
- Immortal time bias in observational studies of drug effectsPharmacoepidemiology and Drug Safety, 2007
- SURVIVAL-TIMES AFTER CARDIAC ALLOGRAFTSThe Lancet, 1969
- Cerebrovascular "Moyamoya" DiseaseArchives of Neurology, 1969